Status:

COMPLETED

Efficacy and Safety of Ranibizumab (Intravitreal Injections) Versus Laser Treatment in Patients With Visual Impairment Due to Diabetic Macular Edema

Lead Sponsor:

Novartis Pharmaceuticals

Conditions:

Diabetic Macular Edema

Visual Impairment

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

This study will assess the efficacy and safety of ranibizumab (intravitreal injections) versus laser treatment in patients with visual impairment due to diabetic macular edema.

Eligibility Criteria

Inclusion

  • Diabetes mellitus 1 or 2, HbA1c \< 11.0%, With: Clinically significant Diabetic Macular Edema in at least one eye.
  • Previous treatment with macular photocoagulation only should be considered if the investigator believes that the study eye may possibly benefit from additional photocoagulation.
  • Best corrected visual acuity score between 78 and 25 letters (Early Treatment Diabetic Retinopathy Study- ETDRS Chart - 4 meters).
  • Central foveal thickness \>250µm (Optical Coherence Tomography).
  • Diabetes medication stable in the 3 months prior.

Exclusion

  • In the study eye:
  • Active intraocular inflammation.
  • Any active infection.
  • History of uveitis.
  • Structural damage within 500 microns of the center of the macula.
  • Neovascularization of the iris.
  • Uncontrolled glaucoma in either eye (Intraocular Pressure \> 24 mmHg).
  • Other protocol-defined inclusion/exclusion criteria may apply.

Key Trial Info

Start Date :

November 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 1 2012

Estimated Enrollment :

83 Patients enrolled

Trial Details

Trial ID

NCT00901186

Start Date

November 1 2009

End Date

August 1 2012

Last Update

March 3 2017

Active Locations (17)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 5 (17 locations)

1

Novartis Investigative Site

Almería, Andalusia, Spain, 04009

2

Novartis Investigative Site

Cadiz, Andalusia, Spain, 11009

3

Novartis Investigative Site

Málaga, Andalusia, Spain, 29010

4

Novartis Investigative Site

Mallorca, Balearic Islands, Spain, 07198